Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
To determine whether a single dose of intravenous lornoxicam is superior to intravenous
placebo for the acute treatment of moderate or severe headache associated with a single
migraine attack in patients with a history of migraine. Two-thirds of patients in this study
will receive a single dose of intravenous lornoxicam (8mg or 16 mg) and one-third of patients
will receive a single dose of an intravenous placebo.